Dexilant capsules are taken by mouth, with or without food, to treat gastroesophageal reflux disease and related acid damage. They contain dexlansoprazole, which reduces stomach acid and supports…
Dexilant capsules are taken by mouth, with or without food, to treat gastroesophageal reflux disease and related acid damage. They contain dexlansoprazole, which reduces stomach acid and supports healing of erosive oesophagitis while relieving heartburn.
Dexilant contains dexlansoprazole, a proton pump inhibitor. This class acts on acid-producing parietal cells in the stomach.
Dexilant contains dexlansoprazole, a proton pump inhibitor. It acts on acid-producing parietal cells in the stomach to reduce stomach acid. The capsules are taken by mouth.
Dexilant contains dexlansoprazole, a proton pump inhibitor. This class acts on acid-producing parietal cells in the stomach, where the hydrogen-potassium adenosine triphosphatase enzyme is responsible for the final step of gastric acid secretion.
Dexlansoprazole is converted to its active form in the acidic environment of the parietal cell canaliculus. It then binds to and inhibits the gastric proton pump. This suppresses acid secretion after meals and during the night, reducing exposure of the oesophagus to damaging stomach acid. The FDA prescribing information describes dexlansoprazole as a proton pump inhibitor used for acid-related gastrointestinal disorders [1].
Lower acid levels give irritated oesophageal tissue time to heal. The medicine also reduces the acidity of refluxed stomach contents, which can lessen burning pain and acid-related irritation.
Dexilant does not work by neutralising acid already present in the stomach. Antacids act within minutes by buffering acid, while dexlansoprazole changes the amount of acid produced by the stomach over a longer period.
Dexilant is used for acid-related conditions involving the oesophagus and upper digestive tract. The main clinical uses include:
Erosive oesophagitis is more than occasional burning after a large meal. Stomach acid repeatedly contacting the oesophageal lining can cause inflammation, shallow erosions, pain, and difficulty swallowing. Dexilant lowers acid exposure so that the tissue can repair itself. Symptom relief may occur before complete mucosal healing, so feeling better does not always mean that the oesophagus has fully recovered.
The medicine is not a general treatment for every cause of stomach pain. It does not directly treat gallbladder disease, pancreatitis, intestinal infection, or swallowing problems caused by a physical narrowing. Persistent vomiting, vomiting blood, black stools, unexplained weight loss, anaemia, or progressive difficulty swallowing requires prompt medical evaluation.
Stomach ulcers can have several causes, including Helicobacter pylori infection and anti-inflammatory medicines. Dexilant may be used in acid-suppression plans, but it is not a complete treatment for H. pylori infection by itself. Ulcer treatment may require antibiotics or a different combination selected by a prescriber.
Several patterns can reduce benefit or make side effects harder to interpret:
A common practical error is judging treatment only by how the person feels after one dose. Acid suppression develops through repeated inhibition of active proton pumps, while tissue healing takes longer than temporary relief.
Dexilant is not suitable for everyone. It should not be used by a person with a previous serious hypersensitivity reaction to dexlansoprazole, other proton pump inhibitors, or an excipient in the formulation.
Dexilant can interact with medicines whose absorption depends on stomach acidity. The New Zealand Medsafe data-sheet information for dexlansoprazole describes interaction considerations involving pH-dependent medicines and selected drugs metabolised through hepatic pathways [3].
Tell the prescriber about warfarin, tacrolimus, methotrexate at high doses, digoxin, clopidogrel, rifampicin, and medicines used for HIV treatment. These combinations do not all have the same level of risk, yet they may require a different medicine, monitoring, or altered timing.
Do not combine Dexilant with another proton pump inhibitor unless the treatment plan specifically says to do so. Taking two acid-suppressing products usually increases exposure without creating a proportional benefit.
Pregnancy and breastfeeding require an individual assessment. The need for acid control, the severity of disease, and available treatment experience should be considered before continuing long-term therapy.
Common adverse effects reported with dexlansoprazole include headache, diarrhoea, abdominal pain, nausea, vomiting, flatulence, constipation, and upper respiratory symptoms. The prescribing information lists these reactions among the known adverse effects of Dexilant [2].
Most reactions are mild. Diarrhoea that is severe, persistent, or accompanied by fever should not be dismissed, because acid suppression can be associated with susceptibility to certain gastrointestinal infections. A rash, facial swelling, wheezing, or difficulty breathing may indicate a serious allergic reaction.
Longer courses and repeated treatment require more careful review. Proton pump inhibitor use has been associated with low magnesium levels, vitamin B12 deficiency after prolonged exposure, acute tubulointerstitial nephritis, bone fractures in selected high-risk patients, and fundic gland polyps. These events are not expected in every person, but the risk profile matters when treatment continues for months or longer.
One practical detail is easy to miss: headache and diarrhoea can be caused by Dexilant, but they can also come from infection, dehydration, dietary changes, or another medicine. The timing of symptoms helps a clinician assess the likely cause.
Another useful detail concerns rebound symptoms. After prolonged proton pump inhibitor use, stopping suddenly can lead to temporary acid-related symptoms in some people. A planned reduction may be appropriate when treatment has continued for a long period.
Dexilant belongs to the proton pump inhibitor group. Other acid-suppression approaches work through different mechanisms and may suit different clinical situations.
| Approach | Main action | Typical clinical role |
|---|---|---|
| Dexilant and other proton pump inhibitors | Reduce the final step of gastric acid secretion | GERD, erosive oesophagitis, and sustained acid control |
| H2-receptor antagonists | Block histamine-driven acid stimulation | Intermittent or less severe acid symptoms in selected patients |
| Antacids and alginates | Neutralise acid or form a temporary barrier | Short-lived relief of occasional symptoms |
Antacids often act faster but wear off sooner. H2-receptor antagonists may help some people with intermittent symptoms, though their acid-suppressing effect is less suited to established erosive damage. Proton pump inhibitors provide stronger suppression for healing, but they should be used at the lowest suitable strength and duration for the treatment objective.
Dexilant’s dual delayed-release formulation may be helpful when acid control is needed across different parts of the day. It can also be less convenient for people who prefer an occasional, short-acting option.
In clinical practice, the first question is usually the treatment target: symptom relief, healing of erosive oesophagitis, or maintenance after healing. The chosen strength and treatment duration should match that target rather than the intensity of a single bad day.
A doctor will also consider whether reflux symptoms are typical. Heartburn and acid regurgitation fit GERD more closely than unexplained chest pressure, persistent vomiting, or progressive swallowing difficulty. Alarm symptoms change the assessment and may lead to endoscopy or other testing.
The FDA prescribing information describes proton pump inhibitors as medicines that suppress gastric acid secretion through inhibition of the gastric proton pump . Their value is strongest when acid is contributing to the problem. They are not designed to mask every upper abdominal symptom indefinitely.
For long-term users, a prescriber may periodically reassess whether Dexilant remains necessary, whether the strength can be reduced, and whether another diagnosis needs investigation. Treatment review is a clinical decision, not a reason to stop abruptly after extended use.
Dexilant may be prescribed for certain patients aged 12 years and older, depending on the indication and strength. Use in younger children requires a separate paediatric assessment and should not be inferred from adult dosing. The FDA label describes age-specific use for selected GERD-related indications, while Medsafe requirements apply to prescribing in New Zealand . A child with recurrent reflux, poor weight gain, vomiting, or swallowing problems needs evaluation for the cause rather than unsupervised acid suppression. The FDA label dated 2022 provides the relevant age-specific prescribing information.
Discuss previous reactions to proton pump inhibitors, liver disease, pregnancy, breastfeeding, swallowing difficulty, gastrointestinal bleeding, unexplained weight loss, and persistent vomiting. Provide a complete list of prescription medicines, over-the-counter products, supplements, and antacids because stomach acidity affects the absorption of some medicines. The clinical review should also establish whether the aim is symptom control, healing of erosive oesophagitis, or maintenance treatment. Medsafe interaction information should guide the review of medicines with pH-dependent absorption . The Medsafe data sheet dated 2023 provides additional interaction details.
Course length depends on the condition being treated, the capsule strength, healing response, and recurrence pattern. Treatment for erosive oesophagitis is often time-limited, while selected patients with recurrent GERD may require longer maintenance. Long-term use can be appropriate when the expected benefit outweighs the risks, with periodic reassessment of the indication and strength. NICE guidance supports reviewing ongoing acid-suppression therapy rather than continuing it automatically without a treatment goal . NICE guidance published in 2014 supports this treatment-review approach.
Dexilant can be combined with some medicines, but the combination should be reviewed when absorption or metabolism may change. Rilpivirine-containing treatment is contraindicated with proton pump inhibitors, and medicines such as warfarin, tacrolimus, digoxin, high-dose methotrexate, and clopidogrel may require focused review. Mineral supplements are not automatically incompatible, yet persistent diarrhoea or prolonged acid suppression may affect nutritional status. The FDA prescribing information provides the interaction framework for dexlansoprazole . The FDA label dated 2022 should be checked before combining dexlansoprazole with other treatments.
Diarrhoea is a recognised adverse effect of Dexilant, although not everyone develops it. Mild loose stools may settle, but persistent watery diarrhoea, fever, abdominal cramping, or blood requires prompt medical assessment. Dehydration can cause dizziness, weakness, and reduced urine output, which should not be attributed to ordinary reflux. The patient information for dexlansoprazole identifies gastrointestinal adverse effects and infection-related warnings that clinicians consider during treatment . The FDA label dated 2022 describes these adverse-effect and infection warnings.
Dexilant is not generally prescribed as a sedative, and many people can drive and work normally while taking it. Headache, dizziness, weakness, blurred vision, or severe diarrhoea can impair concentration in an individual patient. Do not drive or operate machinery if those symptoms affect alertness or coordination. The assessment should also include other medicines, alcohol, dehydration, and the underlying illness, since these may contribute more to impairment than Dexilant itself. The FDA label dated 2022 provides the principal safety information for dexlansoprazole.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
The night-time burning settled during the first week, and I stopped waking with a sour taste. I still had mild bloating after dinner, so I changed the meal timing rather than increasing the capsule.
Queenstown Six weeks 29 Oct 2026The swallowing discomfort improved gradually rather than overnight. I had headaches in the first few days, which eased, but the capsule did not suit me when I took it alongside several other medicines without checking the combination.
Auckland Eight weeks 4 Nov 2026Dexilant controlled the reflux better than occasional antacids had done. I missed a dose during a busy workday and doubled the next one, then felt nauseated, so I stopped doing that.
Dunedin Three months 8 Oct 2026The heartburn was much less frequent, although diarrhoea became troublesome during the second week. My clinician reviewed other possible causes and changed the treatment plan.
Timaru Four weeks 21 Oct 2026
